Conversely, antigen-specific CD8+ T cells use TNF-α as part of their anti-tumor effector arsenal to better support the antibody-dependent cell-mediated cytotoxicity (ADCC) driven by trastuzumab. The gene discussed is CD8A; the disease is neoplasm.